Over two decades of research at Dresden University Medicine has culminated in a breakthrough that could transform how doctors treat blood cancers: catching leukemia relapse before it happens, and stopping it.
The RELAZA2 study, published in the journal Blood, represents the world's first prospective trial to use minimal residual disease (MRD)—tiny traces of cancer cells detected through molecular blood tests—to guide treatment decisions in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The long-term data now available shows that early intervention based on these molecular markers has the potential to significantly delay or even prevent relapses altogether.
The journey began more than twenty years ago, when Prof. Uwe Platzbecker and colleagues at the University Hospital Dresden started asking a radical question: could doctors treat leukemia based on what molecular diagnostics revealed, before patients showed any symptoms? From 2005 to 2011, a pilot study tested this concept in AML patients following stem cell transplantation, then expanded to include patients with NPM1-mutated AML who had undergone conventional therapy. The approach worked well enough to justify a larger, multicenter trial. When RELAZA2's first results published in 2018, they showed promise. Now, with comprehensive long-term data in hand, researchers can confirm that the promise holds.
The key innovation at the heart of this work is precision molecular diagnostics. "The ability to reliably detect even minimal residual disease has fundamentally changed the treatment of AML and MDS," explained Prof. Christian Thiede, laboratory director of the study. What makes this shift historic is that MRD moved from being simply a predictor of disease course—useful for prognosis—to becoming an active guide for treatment itself. When tests detect rising MRD levels, clinicians can now intervene immediately, before relapse becomes clinically apparent.
Prof. Platzbecker reflected on the philosophical shift this represents: "When we began with the first MRD-guided approaches twenty years ago, it was still unclear whether this would actually lead to a new therapeutic pathway. The RELAZA2 long-term data now shows that early intervention based on molecular markers has the potential to significantly influence the course of the disease."
The research was orchestrated primarily through the Study Alliance Leukemia (SAL), a network of leading German leukemia centers that collaborated closely over years. Dr. Anne-Sophie Platzbecker, the study's first author, underscored the human element often invisible in published results: "The RELAZA studies represent a long-term, close collaboration among many centers. Without the dedication of the participating teams and, above all, without the trust of the patients, this development would not have been possible."
Prof. Martin Bornhäuser, Director of Medical Clinic I at UKD, situated this work within a broader vision of how science advances: "This work impressively demonstrates how clinical research can yield new treatment strategies through cooperation over many years. It provides an essential foundation for future studies and personalized treatment approaches."
Rather than viewing these long-term results as an ending, researchers see them as an opening. The next phase involves further refining MRD-guided therapy and embedding it more thoroughly into standard clinical practice. For patients living with these blood cancers, that refinement could mean the difference between relapse and remission—not through chance, but through science that learned to see disease before it could hide.